JPRN-UMIN000000637
Completed
未知
Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer. - Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.
Juntendo University, School of Medicine0 sites20 target enrollmentMarch 16, 2007
Conditionsnon-small cell lung cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- non-small cell lung cancer
- Sponsor
- Juntendo University, School of Medicine
- Enrollment
- 20
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients who have: previous history of hypersensitivity to Gefitinib, uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co\-investigator judged to be inappropriate to participate in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
A phase II trial of gefitinib in combination with bevacizumab as first line therapy for advanced non-small-cell lung cancer with mutated EGFRnon-small-cell lung cancerJPRN-UMIN000004296Okayama Lung Cancer Study Group42
Not yet recruiting
Phase 3
A study to compare Gefitinib tablet with Gefitinib and Chemotherapy inEGFR Mutation Positive Lung cancer patientsHealth Condition 1: C399- Malignant neoplasm of lower respiratory tract, part unspecifiedCTRI/2022/08/044570Tata Memorial Centre
Completed
Not Applicable
Pharmacokinetic study of gefitinib in patients with non-small cell lung cancerAdvanced non-small cell lung cancerJPRN-UMIN000019412Shizuoka cancer center30
Completed
Not Applicable
Analysis of Gefitinib(Drug) in lung cancer.Health Condition 1: null- Lung Cancer PatientsCTRI/2017/05/008490Tata Memorial Hospital350
Completed
Not Applicable
Phase I/II study of Gefitnib monotherapy as neo-adjuvant chemotherapy for cN2 lung adenocarcinoma with the EGFR mutatioJPRN-UMIN000004807KantoKoshinetsu lung cancer research group20